Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 58-year-old woman is evaluated in the hospital prior to being transferred from the intensive care unit to the general medical ward. She was admitted 6 days ago for a severe exacerbation of chronic obstructive pulmonary disease. Her treatment during hospitalization has included intravenous methylprednisolone, nebulized bronchodilators, and prophylactic subcutaneous unfractionated heparin. Her respiratory status has significantly improved.

Serial laboratory studies reveal the following platelet counts:

Hospital DayPlatelet Count
Day 1 (Admission)310,000/mm³
Day 4260,000/mm³
Day 6 (Today)145,000/mm³

On physical examination today, her vital signs are within normal limits. A new, demarcated, erythematous, and exquisitely tender necrotic skin lesion is noted at a recent heparin injection site on her anterior abdomen. There is no mucosal bleeding or petechiae.

Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Continue unfractionated heparin and transfuse apheresis platelets
  2. B
    Discontinue unfractionated heparin and initiate warfarin
  3. Discontinue unfractionated heparin and initiate argatrobanCevap
  4. D
    Discontinue unfractionated heparin and initiate enoxaparin
  5. E
    Continue unfractionated heparin and order a serotonin release assay

Cevap

Discontinue unfractionated heparin and initiate argatroban
The correct management for a patient with a high clinical probability of Heparin-Induced Thrombocytopenia (HIT)—evidenced by a >50% relative drop in platelets starting 5-10 days after heparin initiation and a necrotic skin lesion at the injection site—is to immediately discontinue all heparin products and begin alternative anticoagulation with a non-heparin agent such as a direct thrombin inhibitor (e.g., argatroban).

Adım Adım Çözüm

1
Analyze the patient's laboratory trends and physical exam findings.
The patient experienced a >50% drop in platelet count (from 310,000 to 145,000/mm³) occurring 5 days after starting unfractionated heparin, accompanied by an abdominal necrotic skin lesion at the injection site.
These are hallmark signs of Heparin-Induced Thrombocytopenia (HIT) type II, a severe immune-mediated adverse drug reaction.
2
Determine the necessary treatment modification based on clinical diagnosis.
All forms of heparin must be immediately discontinued.
Continuing heparin will exacerbate the antibody-mediated platelet activation, leading to severe venous or arterial thrombosis.
3
Select the appropriate alternative pharmacotherapy.
Argatroban (or another non-heparin anticoagulant) should be initiated.
Patients with HIT are in a highly prothrombotic state. A direct thrombin inhibitor like argatroban provides safe, immediate anticoagulation without cross-reacting with HIT antibodies.

Anahtar Kavram

Diagnosis and management of Heparin-Induced Thrombocytopenia (HIT) requiring immediate transition to non-heparin anticoagulation.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru